Prime Medicine doses first patient in PM577a Wilson disease trial
Prime Medicine has dosed the first patient in its global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editing therapy targeting H1069Q-mutated Wilson disease. The Cambridge, Massachusetts-based company said the milestone represents the first clinical evaluation of an in vivo Prime Editing therapy from its platform and the opening of its liver franchise. Initial clinical data are expected in 2027.
The US Food and Drug Administration has also granted Rare Pediatric Disease (RPD) designation to PM577, the broader product family of which PM577a is the first candidate. The designation reflects the seriousness of Wilson disease, which typically manifests during childhood and adolescence and affects fewer than 200,000 people in the United States.
The science and the trial
Wilson disease is a rare autosomal recessive disorder caused by loss-of-function mutations in the ATP7B gene, which encodes a copper-transporting ATPase in hepatocytes. Impaired biliary copper excretion leads to progressive accumulation in the liver and, over time, the brain, kidneys and cornea. Existing pharmacological options, primarily copper chelators and zinc salts, require lifelong daily administration and carry tolerability and adherence limitations. Liver transplantation is the only currently curative option but is constrained by organ availability.
PM577a is formulated as a lipid nanoparticle (LNP) and is designed to be delivered as a single intravenous infusion, correcting the H1069Q mutation directly in hepatocytes. The Phase 1/2 study is an open-label, first-in-human, ascending-dose design enrolling adults and adolescents carrying at least one p.H1069Q allele. Initial enrolees will be adults who are clinically stable on standard-of-care therapy. Efficacy measures will include copper efflux assessed by 64Cu PET, serum ceruloplasmin, non-ceruloplasmin-bound copper and 24-hour urinary copper excretion, among others. The trial is registered at ClinicalTrials.gov under NCT07748403.
Chief medical officer Mohammed Asmal said: "PM577a is designed to correct the H1069Q mutation at its genetic root through a single administration, with the potential to offer patients a one-time curative treatment, ideally before irreversible liver and neurological damage occur."
Prime Medicine also has a follow-on candidate in preclinical development targeting the R778L mutation, the most common disease-causing variant in East Asian populations, using the same LNP delivery platform.
Market context and competitive landscape
The Wilson disease therapeutic space has historically attracted limited investment given its rarity, but the emergence of gene and base editing platforms has sharpened industry interest. Prime Medicine's approach sits within the broader in vivo gene editing category, where it competes for scientific credibility and capital with base editing programmes from Beam Therapeutics and in vivo CRISPR efforts from companies including Intellia Therapeutics, each of which has advanced liver-targeted candidates into or toward the clinic.
The RPD designation carries meaningful commercial optionality. Under the FDA's Rare Pediatric Disease Priority Review Voucher programme, a subsequent approval of PM577 could generate a voucher redeemable against a future marketing application or saleable to a third party. PRVs have traded at substantial premiums in recent years, providing a potential non-dilutive revenue source that smaller rare-disease biotechs often factor into their financing strategy.
For Prime Medicine, the first-in-human dosing is also a platform validation event. The company's broader pipeline spans liver, lung, and immunology and oncology programmes, each dependent on demonstrating that Prime Editing can achieve durable, precise genomic correction in a clinical setting. If PM577a generates a clean early safety and biomarker signal in 2027, it is likely to underpin investor confidence across the whole portfolio.